Document is current
Any future updates will be listed below
-
Authors
Tagore, Somnath
Caprio, Lindsay https://orcid.org/0000-0003-1370-8684
Amin, Amit Dipak https://orcid.org/0000-0002-2613-2082
Bestak, Kresimir https://orcid.org/0009-0009-8245-9846
Luthria, Karan https://orcid.org/0000-0002-4392-9675
D’Souza, Edridge https://orcid.org/0000-0003-4664-8163
Barrera, Irving
Melms, Johannes C. https://orcid.org/0000-0002-5410-6586
Wu, Sharon
Abuzaid, Sinan
Wang, Yiping
Jakubikova, Viktoria
Koch, Peter
Brodtman, D. Zack
Bawa, Banpreet
Deshmukh, Sachin K.
Ebel, Leon https://orcid.org/0009-0007-2926-9619
Ibarra-Arellano, Miguel A. https://orcid.org/0000-0001-8411-4854
Jaiswal, Abhinav
Gurjao, Carino
Biermann, Jana
Shaikh, Neha
Ramaradj, Priyanka https://orcid.org/0000-0002-6349-7320
Georgis, Yohanna
Lagos, Galina G. https://orcid.org/0009-0003-6151-6545
Ehrlich, Matthew I.
Ho, Patricia https://orcid.org/0000-0002-4622-8188
Walsh, Zachary H.
Rogava, Meri
Politis, Michelle Garlin https://orcid.org/0000-0003-2501-601X
Biswas, Devanik https://orcid.org/0000-0003-2714-5157
Cottarelli, Azzurra https://orcid.org/0000-0003-4525-2028
Rizvi, Nikhil
Shu, Catherine A. https://orcid.org/0000-0003-0765-7665
Herzberg, Benjamin
Anandasabapathy, Niroshana
Sledge, George
Zorn, Emmanuel https://orcid.org/0000-0001-9985-8389
Canoll, Peter https://orcid.org/0000-0002-7001-0226
Bruce, Jeffrey N. https://orcid.org/0000-0002-6844-0286
Rizvi, Naiyer A.
Taylor, Alison M. https://orcid.org/0000-0001-9341-535X
Saqi, Anjali https://orcid.org/0000-0003-3133-9886
Hibshoosh, Hanina
Schwartz, Gary K.
Henick, Brian S. https://orcid.org/0000-0003-2681-0805
Chen, Fei https://orcid.org/0000-0003-2308-3649
Schapiro, Denis
Shah, Parin
Izar, Benjamin https://orcid.org/0000-0003-2379-6702
- License Information
-
More Information
Article History
Received: 24 January 2023
Accepted: 19 January 2025
First Online: 27 February 2025
Competing interests
: B.I. has received consulting fees and honoraria from Volastra Therapeutics Inc, Merck, AstraZeneca, Novartis, Eisai and Janssen Pharmaceuticals and has received research funding to Columbia University from Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore, Merck, Regeneron and Synthekine. B.I. is a founder of Basima Therapeutics, Inc. C.G. has received consulting fees from Watershed Informatics. B.H. received consulting fees and honoraria from Amgen, Eisai and MJH Life Sciences. A.M.T. received research funding from Ono Pharmaceuticals. N.A.R. is currently an employee and shareholder of Synthekine Inc. B.S.H. has received consulting fees from AstraZeneca, Ideaya, Jazz Pharmaceuticals, Sorrento Therapeutics, Genentech-Roche, OncLive, Veeva, Athenium, Boxer, Dava Oncology and SAI-Med and research funding to Columbia University from Neximmune, Inc, Janssen and Genentech-Roche. A.D.A. is now an employee of Adaptimmune. J.B. is now an employee of Pfizer. S.W., .S.K.D, and G.S. are employees of Caris Life Sciences. A.S. received consulting fees and honoraria from Abbvie, Bristol Myers Squibb, Veracyte, Genentech, Medscape and Physician Education Resource, and research support from Boehringer Ingelheim. All remaining authors report no competing interests.
